https://www.selleckchem.com/pr....oducts/phorbol-12-my
$12,701) and expected QALYs of 15.3 (vs. 14.7 QALYs) per patient, resulting in an ICER value of $13.33 per QALY. From an alternative analysis with a 5-year time horizon, DTG-based ART was found to be dominant, with expected gains of 0.17 QALYs at a lower cost of $1 per patient. The deterministic sensitivity analysis depicted that the maximumincrease inICERvalue was $72 perQALY, and all ICERvalues were below the estimated threshold value. The DTG-based first-line regimen appears to be cost effective compared with
Like
Comment
Share
